DGX Quest Diagnostics Incorporated Common Stock
$245,07
Preço · Ago 24, 2026
Fundamentais a partir de Jul 23, 2026
Intervalo 52 Semanas
$171–$246
99% of range
Classificação do Analista
HOLD
23 analysts
Preço-Alvo
$246
+0% upside
P/E (TTM)
28.3
ROE
14.2%
Margem de Lucro Líquido
9.0%
Sobre Quest Diagnostics Incorporated Common Stock Visão geral da empresa da Wikipedia
Quest Diagnostics Incorporated is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.
Ler mais
Quest Diagnostics Incorporated is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.
As of 2020, the company had approximately 48,000 employees, and it generated more than $7.7 billion in revenue in 2019. The company offers access to diagnostic testing services for cancer, cardiovascular disease, infectious disease, neurological disorders, COVID-19, and employment and court-ordered drug testing.
History
1960–1995
Originally founded as Metropolitan Pathology Laboratory, Inc. in 1967 by Paul A. Brown, MD, the clinical laboratory underwent a variety of name changes. In 1969, the company's name changed to MetPath, Inc. with headquarters in Teaneck, New Jersey. By 1982, MetPath was acquired by what was then known as Corning Glass Works and was subsequently renamed Corning Clinical Laboratories.
1996–2000
On December 31, 1996, Quest Diagnostics became an independent company as a spin-off from Corning. Kenneth W. Freeman was appointed as CEO during this transition. Over the next year, Quest acquired a clinical laboratory division of Branford, Connecticut–based Diagnostic Medical Laboratory, Inc. (DML). Two years later in 1999, Quest added SmithKline Beecham Clinical Laboratories to their subsidiaries; which includes a joint venture ownership with CompuNet Clinical Laboratory. The purchase of SmithKline Beecham also included the lab's medical sample transport airline (ICAO: LBQ, call sign: LABQUEST) originally founded in 1988.
In 1997, Quest and Banner Health formed a joint venture creating the Arizona based Sonora Quest laboratory, a business unit of Laboratory Sciences of Arizona. This entity represents the operations of Quest Diagnostics in the Arizona regional market.
2001–2015
From May 2004 to April 2012, Surya Mohapatra served as the company's President and CEO. In 2007 Quest acquired diagnostic testing equipment company AmeriPath. In response to Mohapatra's resignation after eight years with Quest, former Philips Healthcare CEO Stephen Rusckowski was appointed. Under Rusckowski, Quest Diagnostics teamed up with central New England's largest health care system, UMass Memorial Health Care, to purchase its clinical outreach laboratory.
2016–present
In 2016, Quest collaborated with Safeway to bring testing services to twelve of its stores in California, Maryland, Virginia, Texas and Colorado.
By the end of 2017, Quest, in partnership with Walmart, incorporated laboratory testing in about 15 of their locations in Texas and Florida.
In May 2018, the company announced it will become an in-network laboratory provider to UnitedHealthcare starting in 2019, providing access to 48 million plan members.
In September 2018, Quest moved its headquarters from Madison, where it was located since 2007, to Secaucus, New Jersey.
In November 2018, Quest launched QuestDirect, a consumer-initiated testing service that allows patients to order health and wellness lab testing from home.
In March 2020, the company launched a COVID-19 testing service. As of July 2020, Quest had performed more than 9.2 million COVID-19 molecular tests and 2.8 million serology tests.
In April 2024, Quest has added a new blood screening to their AD-Detect product line. This test will analyze the blood for a specific Alzheimer's protein, pTau-217.
In February 2025, Quest acquired select assets of Fresenius Medical Care's Spectra laboratories. Under a separate agreement, Quest now offers clinical testing and lab services related to dialysis and end-stage kidney disease.
Acquisitions
Partnerships
2005: Forms a strategic alliance with Ciphergen Biosystems to commercialize novel proteomic tests.
Controversies
Quest Diagnostics set a record in April 2009 when it paid $302 million to the government to settle a Medicare fraud case alleging the company sold faulty medical testing kits. It was the largest qui tam (whistleblower) settlement paid by a medical laboratory for manufacturing and distributing a faulty product. In May 2011, Quest paid $241 million to the state of California to settle a False Claims Act case that alleged the company had overcharged Medi-Cal, the state's Medicaid program, and provided illegal kickbacks as incentives for healthcare providers to use Quest labs.
In 2018, Quest Diagnostics was among a number of U.S.–based laboratories linked to inaccuracies of over 200 women's cervical smear tests for CervicalCheck, Ireland's national screening program. Audits of the testing performed by Quest (and another subcontractor, Clinical Pathology Laboratories, Inc. of Austin, Texas) showed a high rate of errors in analysis of samples which led to lawsuits and a government inquiry. Quest and the Irish government continue to settle the resulting lawsuits.
On June 3, 2019, Quest announced that American Medical Collection Agency (AMCA), a billing collections service provider, had informed Quest Diagnostics that an unauthorized user had access to AMCA’s system containing personal information AMCA received from various entities, including from Quest. AMCA provides billing collections services to Optum360, which in turn is a Quest contractor. AMCA later went bankrupt after the breach.
Fonte: Wikipedia (Inglês), CC BY-SA 4.0 · Ver na Wikipedia ↗
DGX Instantâneo da Ação Preço, capitalização de mercado, P/E, EPS, ROE, dívida/patrimônio, intervalo de 52 semanas
Preço
$245.07
Capitalização de Mercado
$27.20B
P/E (TTM)
28.3
EPS (TTM)
$8.75
Receita (TTM)
$11.04B
Rendimento div.
1.3%
ROE
14.2%
Dívida/Capital
0.8
Intervalo 52 Semanas
$171 – $246
DGX Gráfico de Preço da Ação OHLCV diário com indicadores técnicos — panorâmica, zoom e personalize sua visualização
Configure
Desempenho de 10 Anos Tendências de receita, lucro líquido, margens e EPS
Receita e Lucro Líquido
$11.04B
2016-12-31
→
2025-12-31
EPS
$8.75
2016-12-31
→
2025-12-31
Fluxo de caixa livre
$1.36B
2016-12-31
→
2025-12-31
Margens
9.0%
2016-12-31
→
2020-12-31
Avaliação Rácios P/E, P/S, P/B, EV/EBITDA — a ação está cara ou barata?
Métrica
Tendência de 5 anos
DGX
Mediana de Pares
P/E (TTM)
28.3
26.5
P/S (TTM)
2.5
2.0
P/B
3.8
4.9
EV / EBITDA
15.3
—
Price / FCF (Preço / FCF)
20.0
—
Lucratividade Margens bruta, operacional e líquida; ROE, ROA, ROIC
Métrica
Tendência de 5 anos
DGX
Mediana de Pares
Operating Margin (Margem Operacional)
14.1%
—
Net Profit Margin (Margem de Lucro Líquido)
9.0%
4.0%
ROA
6.1%
5.0%
ROE
14.2%
15.2%
ROIC
9.2%
—
Saúde financeira Dívida, liquidez, solvência — força do balanço patrimonial
Métrica
Tendência de 5 anos
DGX
Mediana de Pares
Debt / Equity (Dívida / Patrimônio Líquido)
0.8
—
Current Ratio (Índice de liquidez corrente)
1.0
1.6
Quick Ratio (Índice de Liquidez Seca)
0.8
—
Crescimento Crescimento da receita, EPS e lucro líquido: YoY, CAGR 3 anos, CAGR 5 anos
Métrica
Tendência de 5 anos
DGX
Mediana de Pares
Revenue YoY (Receita Ano a Ano)
11.8%
—
Revenue CAGR 3Y (CAGR Receita 3A)
3.7%
—
Revenue CAGR 5Y (CAGR Receita 5A)
3.2%
—
EPS YoY
13.8%
—
Net Income YoY (Lucro Líquido Ano a Ano)
13.9%
—
Eficiência de Capital Giro de ativos, giro de estoques, giro de contas a receber
Métrica
Tendência de 5 anos
DGX
Mediana de Pares
Payout Ratio (Índice de Pagamento)
35.6%
—
Dividendos Rendimento, índice de pagamento, histórico de dividendos, CAGR de 5 anos
Dividend Yield
1.3%
Índice de Pagamento
35.6%
CAGR Dividendos 5 anos
—
| Data ex | Valor |
|---|---|
| 8 de Julho de 2026 | $0,8600 |
| 6 de Abril de 2026 | $0,8600 |
| 13 de Janeiro de 2026 | $0,8000 |
| 3 de Outubro de 2025 | $0,8000 |
| 7 de Julho de 2025 | $0,8000 |
| 7 de Abril de 2025 | $0,8000 |
| 14 de Janeiro de 2025 | $0,7500 |
| 4 de Outubro de 2024 | $0,7500 |
| 8 de Julho de 2024 | $0,7500 |
| 5 de Abril de 2024 | $0,7500 |
| 16 de Janeiro de 2024 | $0,7100 |
| 5 de Outubro de 2023 | $0,7100 |
| 10 de Julho de 2023 | $0,7100 |
| 6 de Abril de 2023 | $0,7100 |
| 17 de Janeiro de 2023 | $0,6600 |
| 3 de Outubro de 2022 | $0,6600 |
| 5 de Julho de 2022 | $0,6600 |
| 5 de Abril de 2022 | $0,6600 |
| 18 de Janeiro de 2022 | $0,6200 |
| 4 de Outubro de 2021 | $0,6200 |
DGX Consenso dos analistas Opiniões de analistas otimistas e pessimistas, preço-alvo de 12 meses, potencial de alta
COMPRA
23 analistas
- Compra forte 6 26,1%
- Compra 7 30,4%
- Manter 10 43,5%
- Venda 0 0,0%
- Venda forte 0 0,0%
Preço-alvo de 12 meses
15 analistas · 2026-08-23
Mediana
$250.00
Agora
$245.07
Mín
$204.00
Máx
$265.00
Alvo mediano
$250.00
+2,0%
Alvo médio
$245.87
+0,3%
Histórico de Lucros EPS real vs. estimativa, surpresa %, taxa de acerto, próxima data de resultados
Surpresa Média
0.09%
| Período | EPS Actual | EPS est. | Surpresa |
|---|---|---|---|
| 30 de Junho de 2026 | $3.12 | $2.85 | 0.27% |
| 31 de Março de 2026 | $2.50 | $2.37 | 0.13% |
| 31 de Dezembro de 2025 | $2.42 | $2.38 | 0.04% |
| 30 de Setembro de 2025 | $2.60 | $2.53 | 0.07% |
| 30 de Junho de 2025 | $2.62 | $2.60 | 0.02% |
| 31 de Março de 2025 | $2.21 | $2.17 | 0.04% |
Comparação de pares (subindústria GICS) Métricas chave vs pares do setor
| Ticker | Capitalização de Mercado | P/E | Receita YoY | Margem Líquida | ROE | Margem Bruta |
|---|---|---|---|---|---|---|
| DGX | $19.09B | 19.8 | 11.8% | 9.0% | 14.2% | — |
| CVS | $100.87B | 57.1 | 7.8% | 0.44% | 2.4% | — |
| CI | $72.51B | 12.4 | 11.2% | 2.2% | 14.4% | — |
| LH | $20.62B | 24.0 | 7.2% | 6.3% | 10.3% | 28.8% |
| GH | $13.34B | -30.8 | 32.9% | -42.4% | 205.7% | — |
| LH | $20.62B | 24.0 | 7.2% | 6.3% | 10.3% | 28.8% |
| BTSG | $7.20B | 43.0 | 28.2% | 1.5% | 10.8% | 11.8% |
| DVA | $7.79B | 11.5 | 6.5% | 5.5% | -281.8% | — |
| HIMS | — | 63.7 | 59.0% | 5.5% | 23.3% | 73.8% |
| HNGE | $0 | -6.0 | 50.6% | -89.9% | -299.8% | 79.7% |
| CHE | — | 23.3 | 4.1% | 10.5% | 24.4% | — |
Fundamentos Completos Todas as métricas por ano — demonstração de resultados, balanço patrimonial, fluxo de caixa
Demonstração de Resultados 17
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.04B | $9.87B | $9.25B | $9.88B | $10.79B | $9.44B | $7.73B | $7.53B | $7.40B | $7.21B | $7.49B | $7.43B | |
| Cost of Revenue | $7.37B | $6.63B | $6.20B | $6.45B | $6.58B | $5.80B | $5.04B | $4.93B | $4.72B | $4.62B | $4.66B | $4.64B | |
| Gross Profit | · | · | · | · | · | $3.63B | $2.69B | $2.60B | $2.68B | $2.90B | $2.84B | $2.80B | |
| SG&A Expense | $1.97B | $1.77B | $1.64B | $1.87B | $1.73B | $1.55B | $1.46B | $1.42B | $1.44B | $1.38B | $1.68B | $1.73B | |
| Operating Expenses | $9.48B | $8.53B | $7.99B | $8.46B | $8.41B | $7.47B | $6.50B | $6.43B | $6.24B | $5.94B | $6.09B | $6.45B | |
| Operating Income | $1.56B | $1.35B | $1.26B | $1.43B | $2.38B | $1.97B | $1.23B | $1.10B | $1.17B | $1.28B | $1.40B | $983M | |
| Interest Expense | · | · | $163M | $148M | $152M | $166M | $180M | $169M | $153M | $144M | $154M | $167M | |
| Interest Income | $13M | $25M | $11M | $10M | $1M | $3M | $5M | $2M | $2M | $1M | $1M | $3M | |
| Other Non-op | $26M | $30M | $20M | $-55M | $369M | $76M | $20M | $-8M | $16M | $-48M | $-143M | $4M | |
| Pretax Income | $1.32B | $1.18B | $1.13B | $1.24B | $2.60B | $1.88B | $1.08B | $926M | $1.03B | $1.09B | $1.10B | $823M | |
| Income Tax | $314M | $273M | $248M | $264M | $597M | $460M | $247M | $182M | $241M | $429M | $373M | $262M | |
| Net Income | $992M | $871M | $854M | $946M | $2.00B | $1.43B | $858M | $736M | $772M | $645M | $709M | $556M | |
| EPS (Basic) | $8.87 | $7.78 | $7.59 | $8.10 | $15.85 | $10.62 | $6.36 | $5.39 | $5.63 | $4.58 | $4.92 | $3.83 | |
| EPS (Diluted) | $8.75 | $7.69 | $7.49 | $7.97 | $15.55 | $10.47 | $6.28 | $5.29 | $5.50 | $4.51 | $4.87 | $3.81 | |
| Shares (Basic) | 111,000,000 | 111,000,000 | 112,000,000 | 116,000,000 | 125,000,000 | 134,000,000 | 134,000,000 | 136,000,000 | 137,000,000 | 140,000,000 | 144,000,000 | 145,000,000 | |
| Shares (Diluted) | 113,000,000 | 113,000,000 | 113,000,000 | 118,000,000 | 128,000,000 | 136,000,000 | 136,000,000 | 139,000,000 | 140,000,000 | 142,000,000 | 145,000,000 | 145,000,000 | |
| EBITDA | $2.13B | $1.84B | $1.70B | $1.86B | $2.79B | $2.33B | $1.56B | $1.41B | $1.44B | $1.53B | $1.70B | $1.30B |
Balanço Patrimonial 27
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $420M | $549M | $686M | $315M | $872M | $1.16B | $1.19B | $135M | $137M | $359M | $133M | $192M | |
| Receivables | $1.41B | $1.30B | $1.21B | $1.20B | $1.44B | $1.52B | $1.06B | $1.01B | $924M | $926M | $901M | $932M | |
| Inventory | $189M | $188M | $190M | $192M | $208M | $223M | $123M | $99M | $95M | $82M | $84M | $110M | |
| Prepaid Expense | $361M | $351M | $286M | $196M | $223M | $157M | $112M | $144M | $150M | $155M | $207M | $186M | |
| Current Assets | $2.38B | $2.39B | $2.37B | $1.90B | $2.74B | $3.06B | $2.49B | $1.39B | $1.31B | $1.53B | $1.50B | $1.60B | |
| PP&E (Net) | $2.20B | $2.11B | $1.82B | $1.77B | $1.71B | $1.63B | $1.45B | $1.29B | $1.15B | $1.03B | $925M | $933M | |
| PP&E (Gross) | $6.18B | $5.77B | $5.23B | $5.10B | $4.79B | $4.62B | $4.23B | $3.97B | $3.67B | $3.43B | $3.23B | $3.13B | |
| Accum. Depreciation | $3.97B | $3.66B | $3.42B | $3.34B | $3.09B | $2.99B | $2.78B | $2.68B | $2.53B | $2.40B | $2.31B | $2.19B | |
| Goodwill | $8.95B | $8.86B | $7.73B | $7.22B | $7.09B | $6.87B | $6.62B | $6.56B | $6.33B | $6.00B | $5.91B | $6.03B | |
| Intangibles | $1.64B | $1.76B | $1.17B | $1.09B | $1.17B | $1.17B | $1.12B | $1.21B | $1.12B | $949M | $984M | $1.07B | |
| Other Non-current Assets | $270M | $255M | $198M | $144M | $163M | $176M | $160M | $119M | $136M | $148M | $174M | $172M | |
| Total Assets | $16.23B | $16.15B | $14.02B | $12.84B | $13.61B | $14.03B | $12.84B | $11.00B | $10.50B | $10.10B | $9.96B | $9.86B | |
| Accounts Payable | $1.60B | $1.39B | $1.36B | $1.40B | $1.60B | $1.63B | $1.04B | $1.02B | $1.02B | $975M | $1.01B | $1.19B | |
| Accrued Liabilities | $338M | $306M | $287M | $392M | $460M | $356M | $223M | $274M | $246M | $254M | $257M | $277M | |
| Current Liabilities | $2.28B | $2.17B | $1.81B | $1.55B | $1.75B | $1.78B | $1.99B | $1.49B | $1.06B | $981M | $1.17B | $1.71B | |
| Capital Leases | $537M | $535M | $503M | $489M | $494M | $499M | $413M | $0 | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | $264M | $243M | $170M | $191M | $157M | $204M | |
| Other Non-current Liabilities | $957M | $938M | $876M | $812M | $792M | $847M | $711M | $745M | $663M | $654M | $514M | $594M | |
| Long-term Debt | $5.67B | $6.22B | $4.71B | $3.98B | $4.01B | $4.01B | $4.77B | $3.89B | $3.78B | $3.73B | $3.65B | $3.74B | |
| Total Debt | $5.67B | $6.22B | $4.71B | $3.98B | $4.01B | $4.01B | $4.77B | $3.89B | $3.78B | $3.73B | $3.65B | $3.76B | |
| Common Stock | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Retained Earnings | $9.99B | $9.36B | $8.82B | $8.29B | $7.65B | $9.30B | $8.17B | $7.60B | $7.14B | $6.61B | $6.20B | $5.72B | |
| Treasury Stock | $5.18B | $4.86B | $4.83B | $4.67B | $3.45B | $5.37B | $5.22B | $5.00B | $4.78B | $4.46B | $3.96B | $3.81B | |
| AOCI | $-27M | $-88M | $-14M | $-21M | $-14M | $-21M | $-39M | $-59M | $-48M | $-72M | $-38M | $-27M | |
| Stockholders' Equity | $7.17B | $6.78B | $6.31B | $5.89B | $6.44B | $6.76B | $5.64B | $5.22B | $4.92B | $4.63B | $4.68B | $4.30B | |
| Liabilities + Equity | $16.23B | $16.15B | $14.02B | $12.84B | $13.61B | $14.03B | $12.84B | $11.00B | $10.50B | $10.10B | $9.96B | $9.86B | |
| Shares Outstanding | 110,000,000 | 111,000,000 | 111,000,000 | 111,000,000 | 119,000,000 | 133,000,000 | 133,000,000 | 135,000,000 | 135,000,000 | 137,000,000 | 143,000,000 | 144,000,000 |
Fluxo de Caixa 17
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $570M | $493M | $439M | $437M | $408M | $361M | $329M | $309M | $270M | $249M | $304M | $314M | |
| Stock-based Comp | $88M | $88M | $77M | $77M | $79M | $97M | $56M | $61M | $79M | $69M | $52M | $51M | |
| Deferred Tax | $105M | $13M | $-49M | $1M | $-57M | $85M | $15M | $73M | $9M | $37M | $112M | $23M | |
| Amort. of Intangibles | $154M | $127M | $108M | $120M | $103M | $103M | $96M | $90M | $74M | $72M | $81M | $94M | |
| Restructuring | · | · | · | $55M | $13M | $14M | $-3M | $49M | $30M | $11M | $39M | $43M | |
| Other Non-cash | $131M | $-131M | $-49M | $257M | $-192M | $31M | $-15M | $21M | $45M | $69M | $-367M | $-6M | |
| Operating Cash Flow | $1.89B | $1.33B | $1.27B | $1.72B | $2.23B | $2.00B | $1.24B | $1.20B | $1.18B | $1.12B | $821M | $944M | |
| CapEx | $527M | $425M | $408M | $404M | $403M | $418M | $400M | $383M | $252M | $293M | $263M | $308M | |
| Investing Cash Flow | $-631M | $-2.55B | $-1.06B | $-543M | $21M | $-772M | $-411M | $-801M | $-830M | $-127M | $-362M | $-1.02B | |
| Stock Repurchased | $450M | $151M | $275M | $1.41B | $2.20B | $325M | $353M | $322M | $465M | $590M | $224M | $132M | |
| Net Stock Activity | $-450M | $-151M | $-275M | $-1.41B | $-2.20B | $-325M | $-353M | $-322M | $-465M | $-590M | $-224M | $-132M | |
| Dividends Paid | $353M | $331M | $314M | $305M | $309M | $297M | $286M | $266M | $247M | $223M | $212M | $187M | |
| Financing Cash Flow | $-1.39B | $1.08B | $160M | $-1.73B | $-2.54B | $-1.27B | $225M | $-401M | $-592M | $-738M | $-518M | $86M | |
| Net Change in Cash | $-129M | $-137M | $371M | $-557M | $-286M | · | · | · | $-222M | $226M | $-59M | $5M | |
| Taxes Paid | $169M | $256M | $317M | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $1.36B | $909M | $864M | $1.31B | $1.83B | $1.59B | $843M | $817M | $923M | $776M | $547M | $630M | |
| Levered FCF | · | · | $737M | $1.20B | $1.71B | $1.46B | $704M | $681M | $806M | $689M | · | · |
Lucratividade 8
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | · | · | · | · | 38.5% | 34.8% | 34.6% | 38.8% | 38.6% | 37.9% | 37.6% | |
| Operating Margin | 14.1% | 13.6% | 13.6% | 14.4% | 22.1% | 20.9% | 15.9% | 14.6% | 15.1% | 17.0% | 18.7% | 13.2% | |
| Net Margin | 9.0% | 8.8% | 9.2% | 9.6% | 18.5% | 15.2% | 11.1% | 9.8% | 10.0% | 8.6% | 9.5% | 7.5% | |
| Pretax Margin | 11.9% | 11.9% | 12.2% | 12.5% | 24.1% | 20.0% | 13.9% | 12.3% | 13.4% | 14.4% | 14.7% | · | |
| EBITDA Margin | 19.3% | 18.6% | 18.4% | 18.9% | 25.9% | 24.7% | 20.2% | 18.7% | 18.6% | 20.3% | 22.7% | 17.4% | |
| ROA | 6.1% | 5.8% | 6.4% | 7.1% | 14.4% | 10.7% | 7.2% | 6.8% | 7.5% | 6.4% | 7.1% | 5.9% | |
| ROE | 14.2% | 13.3% | 14.0% | 15.3% | 30.2% | 23.1% | 15.8% | 14.5% | 16.2% | 13.9% | 15.8% | 13.5% | |
| ROIC | 9.2% | 8.0% | 8.9% | 11.4% | 17.5% | 13.8% | 9.1% | 9.7% | 10.2% | 9.2% | 11.1% | · |
Liquidez e Solvência 5
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.0 | 1.1 | 1.3 | 1.2 | 1.6 | 1.7 | 1.3 | 0.9 | 1.2 | 1.6 | 1.3 | 0.9 | |
| Quick Ratio | 0.8 | 0.9 | 1.0 | 1.0 | 1.3 | 1.5 | 1.1 | 0.8 | 1.0 | 1.3 | 0.9 | 0.7 | |
| Debt / Equity | 0.8 | 0.9 | 0.7 | 0.7 | 0.6 | 0.6 | 0.8 | 0.7 | 0.8 | 0.8 | 0.8 | 0.9 | |
| LT Debt / Equity | 0.7 | 0.8 | 0.7 | 0.7 | 0.6 | 0.6 | 0.7 | 0.7 | 0.8 | 0.8 | 0.7 | 0.8 | |
| Interest Coverage | · | · | 7.7 | 9.6 | 15.7 | 11.9 | 6.8 | 6.5 | 7.6 | 8.9 | · | · |
Eficiência 3
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.7 | 0.7 | 0.7 | 0.7 | 0.8 | 0.7 | 0.6 | 0.7 | 0.7 | 0.7 | 0.8 | 0.8 | |
| Inventory Turnover | 39.1 | 35.1 | 32.5 | 32.2 | 30.5 | 33.5 | 45.4 | 50.8 | 53.3 | 55.6 | 48.0 | 46.1 | |
| Receivables Turnover | 8.1 | 7.9 | 7.7 | 7.5 | 7.3 | 7.3 | 7.4 | 7.8 | 8.3 | 8.2 | 8.2 | 8.3 |
Taxas de Crescimento 10
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 11.8% | 6.7% | -6.4% | -8.4% | 14.3% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 3.7% | -2.9% | -0.66% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 3.2% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 13.8% | 2.7% | -6.0% | -48.8% | 48.5% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 3.2% | -20.9% | -10.6% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | -3.5% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 13.9% | 2.0% | -9.7% | -52.6% | 39.4% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 1.6% | -24.1% | -15.8% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | -7.1% | · | · | · | · | · | · | · | · | · | · | · | |
| Dividend CAGR 5Y | 3.5% | · | · | · | · | · | · | · | · | · | · | · |
Avaliação (TTM) 16
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $11.04B | $9.87B | $9.25B | $9.88B | $10.79B | $9.44B | $7.73B | $7.53B | $7.40B | $7.21B | $7.49B | $7.43B | |
| Net Income TTM | $992M | $871M | $854M | $946M | $2.00B | $1.43B | $858M | $736M | $772M | $645M | $709M | $556M | |
| Market Cap | $19.09B | $16.75B | $15.30B | $17.36B | $20.59B | $15.85B | $14.20B | $11.24B | $13.30B | $12.59B | $10.17B | $9.66B | |
| Enterprise Value | $24.34B | $22.41B | $19.33B | $21.03B | $23.73B | $18.71B | $17.78B | $15.00B | $16.94B | $15.97B | $13.69B | $13.23B | |
| P/E | 19.8 | 19.6 | 18.4 | 19.6 | 11.1 | 11.4 | 17.0 | 15.7 | 17.9 | 20.4 | 14.6 | 17.6 | |
| P/S | 1.7 | 1.7 | 1.7 | 1.8 | 1.9 | 1.7 | 1.8 | 1.5 | 1.8 | 1.7 | 1.4 | 1.3 | |
| P/B | 2.7 | 2.5 | 2.4 | 2.9 | 3.2 | 2.3 | 2.5 | 2.2 | 2.7 | 2.7 | 2.2 | 2.2 | |
| P / Cash Flow | 10.1 | 12.6 | 12.0 | 10.1 | 9.2 | 7.9 | 11.4 | 9.4 | 11.3 | 11.8 | 12.6 | 10.3 | |
| P / FCF | 14.0 | 18.4 | 17.7 | 13.2 | 11.3 | 10.0 | 16.8 | 13.8 | 14.4 | 16.2 | 18.6 | 15.3 | |
| EV / EBITDA | 11.4 | 12.2 | 11.4 | 11.3 | 8.5 | 8.0 | 11.4 | 10.6 | 11.8 | 10.5 | 8.0 | 10.2 | |
| EV / FCF | 17.9 | 24.7 | 22.4 | 16.0 | 13.0 | 11.8 | 21.1 | 18.4 | 18.4 | 20.6 | 25.0 | 21.0 | |
| EV / Revenue | 2.2 | 2.3 | 2.1 | 2.1 | 2.2 | 2.0 | 2.3 | 2.0 | 2.3 | 2.2 | 1.8 | 1.8 | |
| Dividend Yield | 1.8% | 2.0% | 2.1% | 1.8% | 1.5% | 1.9% | 2.0% | 2.4% | 1.9% | 1.8% | 2.1% | 1.9% | |
| Earnings Yield | 5.0% | 5.1% | 5.4% | 5.1% | 9.0% | 8.8% | 5.9% | 6.3% | 5.6% | 4.9% | 6.9% | 5.7% | |
| Payout Ratio | 35.6% | 38.0% | 36.8% | 32.2% | 15.5% | 20.8% | 33.3% | 36.1% | 32.0% | 34.6% | 29.9% | 33.6% | |
| Annual Payout | $353M | $331M | $314M | $305M | $309M | $297M | $286M | $266M | $247M | $223M | $212M | $187M |
Demonstração de Resultados 16
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.04B | $2.90B | $2.81B | $2.82B | $2.76B | $2.65B | $2.62B | $2.49B | $2.40B | $2.37B | $2.29B | $2.29B | $2.34B | $2.33B | $2.33B | $2.49B | |
| Cost of Revenue | $2.02B | $1.95B | $1.90B | $1.87B | $1.82B | $1.79B | $1.76B | $1.68B | $1.59B | $1.59B | $1.55B | $1.54B | $1.55B | $1.56B | $1.57B | $1.62B | |
| SG&A Expense | $529M | $504M | $504M | $501M | $486M | $476M | $466M | $448M | $416M | $440M | $407M | $380M | $416M | $439M | $563M | $464M | |
| Operating Expenses | $2.58B | $2.50B | $2.42B | $2.43B | $2.32B | $2.31B | $2.26B | $2.16B | $2.04B | $2.07B | $2.02B | $1.95B | $1.99B | $2.03B | $2.20B | $2.09B | |
| Operating Income | $459M | $399M | $386M | $386M | $438M | $346M | $361M | $330M | $355M | $300M | $267M | $342M | $348M | $305M | $135M | $392M | |
| Interest Expense | · | · | · | · | · | · | · | · | $47M | $49M | · | $41M | $39M | $37M | · | $37M | |
| Interest Income | $5M | $2M | $3M | $3M | $2M | $5M | $7M | $9M | $3M | $6M | $6M | $1M | $2M | $2M | $4M | $4M | |
| Other Non-op | $16M | $-2M | $8M | $8M | $13M | $-3M | $3M | $15M | $3M | $9M | $10M | $-3M | $6M | $7M | $6M | $-8M | |
| Pretax Income | $412M | $334M | $330M | $328M | $384M | $276M | $299M | $296M | $314M | $266M | $237M | $299M | $317M | $277M | $109M | $351M | |
| Income Tax | $88M | $74M | $81M | $77M | $97M | $59M | $68M | $65M | $74M | $66M | $40M | $68M | $75M | $65M | $-4M | $81M | |
| Net Income | $320M | $252M | $245M | $245M | $282M | $220M | $222M | $226M | $229M | $194M | $192M | $225M | $235M | $202M | $101M | $256M | |
| EPS (Basic) | $2.88 | $2.27 | $2.21 | $2.18 | $2.51 | $1.97 | $1.98 | $2.01 | $2.05 | $1.74 | $1.72 | $1.99 | $2.08 | $1.80 | $0.93 | $2.20 | |
| EPS (Diluted) | $2.84 | $2.24 | $2.18 | $2.16 | $2.47 | $1.94 | $1.95 | $1.99 | $2.03 | $1.72 | $1.70 | $1.96 | $2.05 | $1.78 | $0.92 | $2.17 | |
| Shares (Basic) | 111,000,000 | 110,000,000 | -224,000,000 | 112,000,000 | 112,000,000 | 111,000,000 | -223,000,000 | 112,000,000 | 111,000,000 | 111,000,000 | -224,000,000 | 112,000,000 | 112,000,000 | 112,000,000 | -236,000,000 | 116,000,000 | |
| Shares (Diluted) | 112,000,000 | 112,000,000 | -226,000,000 | 113,000,000 | 113,000,000 | 113,000,000 | -224,000,000 | 113,000,000 | 112,000,000 | 112,000,000 | -228,000,000 | 114,000,000 | 114,000,000 | 113,000,000 | -240,000,000 | 118,000,000 | |
| EBITDA | $605M | $546M | · | $528M | $581M | $486M | · | $455M | $472M | $416M | · | $453M | $460M | $412M | · | $500M |
Balanço Patrimonial 26
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $626M | $393M | $420M | $432M | $319M | $188M | $549M | $764M | $271M | $474M | · | $143M | $126M | $175M | · | $700M | |
| Receivables | $1.67B | $1.59B | $1.41B | $1.46B | $1.42B | $1.40B | $1.30B | $1.38B | $1.32B | $1.32B | · | $1.28B | $1.24B | $1.25B | · | $1.28B | |
| Inventory | $233M | $225M | $189M | $186M | $187M | $189M | $188M | $184M | $182M | $181M | · | $184M | $184M | $190M | · | $183M | |
| Prepaid Expense | $319M | $361M | $361M | $333M | $273M | $294M | $351M | $299M | $245M | $251M | · | $207M | $188M | $195M | · | $171M | |
| Current Assets | $2.84B | $2.57B | $2.38B | $2.41B | $2.20B | $2.08B | $2.39B | $2.62B | $2.02B | $2.23B | · | $1.81B | $1.73B | $1.81B | · | $2.33B | |
| PP&E (Net) | $2.22B | $2.19B | $2.20B | $2.15B | $2.12B | $2.10B | $2.11B | $2.09B | $1.83B | $1.81B | · | $1.83B | $1.81B | $1.79B | · | $1.71B | |
| PP&E (Gross) | · | · | $6.18B | · | · | · | $5.77B | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $3.97B | · | · | · | $3.66B | · | · | · | · | · | · | · | · | · | |
| Goodwill | $9.11B | $9.12B | $8.95B | $8.90B | $8.88B | $8.85B | $8.86B | $8.61B | $7.88B | $7.83B | $7.73B | $7.73B | $7.73B | $7.24B | $7.22B | $7.19B | |
| Intangibles | $1.67B | $1.72B | $1.64B | $1.66B | $1.71B | $1.73B | $1.76B | $1.72B | $1.20B | $1.19B | · | $1.22B | $1.25B | $1.08B | · | $1.11B | |
| Other Non-current Assets | $277M | $256M | $270M | $296M | $271M | $260M | $255M | $272M | $216M | $182M | · | $149M | $152M | $150M | · | $132M | |
| Total Assets | $16.94B | $16.67B | $16.23B | $16.20B | $15.97B | $15.80B | $16.15B | $16.09B | $13.88B | $13.95B | · | $13.48B | $13.43B | $12.79B | · | $13.22B | |
| Accounts Payable | $1.60B | $1.50B | $1.60B | $1.46B | $1.35B | $1.27B | $1.39B | $1.31B | $1.25B | $1.24B | · | $1.16B | $1.20B | $1.20B | · | $1.45B | |
| Accrued Liabilities | · | · | $338M | · | · | · | $306M | · | · | · | · | · | · | · | · | · | |
| Current Liabilities | $1.79B | $2.18B | $2.28B | $2.13B | $2.02B | $1.44B | $2.17B | $2.09B | $2.01B | $2.30B | · | $1.62B | $1.88B | $1.35B | · | $1.60B | |
| Capital Leases | $561M | $574M | $537M | $534M | $540M | $538M | $535M | $543M | $507M | $489M | · | $505M | $508M | $490M | · | $505M | |
| Other Non-current Liabilities | $1.06B | $1.02B | $957M | $982M | $890M | $917M | $938M | $891M | $811M | $817M | · | $874M | $901M | $809M | · | $787M | |
| Long-term Debt | $5.64B | · | $5.67B | · | · | · | $6.22B | $6.25B | · | · | · | · | · | · | · | · | |
| Total Debt | $5.64B | $503M | · | $504M | $504M | $1M | · | $6.25B | $606M | $906M | · | $304M | $518M | $2M | · | $2M | |
| Common Stock | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | $2M | $2M | $2M | · | $2M | |
| Retained Earnings | $10.37B | $10.15B | $9.99B | $9.84B | $9.68B | $9.49B | $9.36B | $9.22B | $9.08B | $8.94B | · | $8.71B | $8.57B | $8.41B | · | $8.26B | |
| Treasury Stock | $5.17B | $5.09B | $5.18B | $4.90B | $4.77B | $4.79B | $4.86B | $4.73B | $4.76B | $4.78B | · | $4.57B | $4.59B | $4.61B | · | $4.27B | |
| AOCI | $-62M | $-43M | $-27M | $-40M | $-16M | $-83M | $-88M | $-15M | $-19M | $-16M | · | $-20M | $-16M | $-18M | · | $-31M | |
| Stockholders' Equity | $7.52B | $7.37B | $7.17B | $7.26B | $7.23B | $6.93B | $6.78B | $6.81B | $6.62B | $6.43B | · | $6.42B | $6.25B | $6.05B | · | $6.24B | |
| Liabilities + Equity | $16.94B | $16.67B | $16.23B | $16.20B | $15.97B | $15.80B | $16.15B | $16.09B | $13.88B | $13.95B | · | $13.48B | $13.43B | $12.79B | · | $13.22B | |
| Shares Outstanding | 110,000,000 | 111,000,000 | 110,000,000 | 111,000,000 | 112,000,000 | 112,000,000 | 111,000,000 | 112,000,000 | 111,000,000 | 111,000,000 | 111,000,000 | 112,000,000 | 112,000,000 | 112,000,000 | 111,000,000 | 114,000,000 |
Fluxo de Caixa 16
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $146M | $147M | $145M | $142M | $143M | $140M | $135M | $125M | $117M | $116M | $109M | $111M | $112M | $107M | $116M | $108M | |
| Stock-based Comp | $23M | $20M | $25M | $20M | $21M | $22M | $27M | $19M | $20M | $22M | $19M | $18M | $16M | $24M | $22M | $18M | |
| Deferred Tax | $-2M | $48M | $-13M | $110M | $1M | $7M | $34M | $15M | $-18M | $-18M | $-10M | $-23M | $-12M | $-4M | $-44M | $65M | |
| Amort. of Intangibles | $38M | $37M | $37M | $39M | $39M | $39M | $37M | $32M | $29M | $29M | $27M | $27M | $28M | $26M | $39M | $27M | |
| Restructuring | · | · | · | $6M | $1M | · | · | $7M | $8M | · | · | $1M | $1M | · | · | · | |
| Other Non-cash | · | $-189M | · | · | · | $-75M | · | · | · | $-160M | · | · | · | $-235M | · | · | |
| Operating Cash Flow | $597M | $278M | $465M | $563M | $544M | $314M | $464M | $356M | $360M | $154M | $527M | $207M | $444M | $94M | $334M | $502M | |
| CapEx | $138M | $114M | $158M | $144M | $108M | $117M | $123M | $106M | $92M | $104M | $72M | $105M | $104M | $127M | $147M | $118M | |
| Investing Cash Flow | $-134M | $-152M | $-191M | $-201M | $-124M | $-115M | $-502M | $-1.63B | $-200M | $-213M | $-114M | $-107M | $-682M | $-158M | $-174M | $-118M | |
| Stock Repurchased | · | · | $300M | $150M | · | · | $151M | · | · | · | $275M | $0 | $0 | $0 | $461M | $374M | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | · | |
| Dividends Paid | $96M | $88M | $90M | $89M | $90M | $84M | $84M | $84M | $84M | $79M | $80M | $80M | $80M | $74M | $75M | $78M | |
| Financing Cash Flow | $-229M | $-152M | $-287M | $-247M | $-293M | $-561M | $-170M | $1.77B | $-363M | $-153M | $130M | $-83M | $189M | $-76M | $-545M | $-474M | |
| Net Change in Cash | $233M | $-27M | $-12M | $113M | $131M | $-361M | $-215M | $493M | $-203M | $-212M | $543M | $17M | $-49M | $-140M | $-385M | $-90M | |
| Free Cash Flow | · | $164M | · | · | · | $197M | · | · | · | $50M | · | · | · | $-33M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $13M | · | · | · | $-61M | · | · |
Lucratividade 7
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 15.1% | 13.8% | · | 13.7% | 15.9% | 13.1% | · | 13.3% | 14.8% | 12.7% | · | 14.9% | 14.9% | 13.1% | · | 15.8% | |
| Net Margin | 10.5% | 8.7% | · | 8.7% | 10.2% | 8.3% | · | 9.1% | 9.6% | 8.2% | · | 9.8% | 10.1% | 8.7% | · | 10.3% | |
| Pretax Margin | 13.5% | 11.5% | · | 11.7% | 13.9% | 10.4% | · | 11.9% | 13.1% | 11.2% | · | 13.0% | 13.6% | 11.9% | · | 14.1% | |
| EBITDA Margin | 19.9% | 18.9% | · | 18.8% | 21.0% | 18.3% | · | 18.3% | 19.7% | 17.6% | · | 19.7% | 19.7% | 17.7% | · | 20.1% | |
| ROA | 1.9% | 1.6% | · | 1.5% | 1.9% | 1.5% | · | 1.5% | 1.7% | 1.5% | · | 1.7% | 1.8% | 1.5% | · | 1.9% | |
| ROE | 4.3% | 3.5% | · | 3.5% | 4.1% | 3.3% | · | 3.4% | 3.6% | 3.1% | · | 3.5% | 3.7% | 3.2% | · | 4.0% | |
| ROIC | 2.7% | 4.0% | · | 3.8% | 4.2% | 3.9% | · | 2.0% | 3.8% | 3.1% | · | 3.9% | 3.9% | 3.9% | · | 4.8% |
Liquidez e Solvência 5
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.6 | 1.2 | · | 1.1 | 1.1 | 1.4 | · | 1.3 | 1.0 | 1.0 | · | 1.1 | 0.9 | 1.3 | · | 1.5 | |
| Quick Ratio | 1.3 | 0.9 | · | 0.9 | 0.9 | 1.1 | · | 1.0 | 0.8 | 0.8 | · | 0.9 | 0.7 | 1.1 | · | 1.2 | |
| Debt / Equity | 0.8 | 0.1 | · | 0.1 | 0.1 | 0.0 | · | 0.9 | 0.1 | 0.1 | · | 0.0 | 0.1 | 0.0 | · | 0.0 | |
| LT Debt / Equity | 0.7 | · | · | · | · | · | · | 0.8 | · | · | · | · | · | · | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | 7.6 | 6.1 | · | 8.3 | 8.9 | 8.2 | · | 10.6 |
Eficiência 3
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | |
| Inventory Turnover | 9.6 | 9.4 | · | 10.1 | 9.9 | 9.7 | · | 9.1 | 8.7 | 8.6 | · | 8.4 | 8.3 | 8.1 | · | 8.3 | |
| Receivables Turnover | 2.0 | 1.9 | · | 2.0 | 2.0 | 1.9 | · | 1.9 | 1.9 | 1.8 | · | 1.8 | 1.8 | 1.8 | · | 1.8 |
Avaliação (TTM) 14
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $11.52B | $11.12B | · | $10.72B | $10.30B | $9.90B | · | $9.55B | $9.40B | $9.33B | · | $9.45B | $9.61B | $9.88B | · | $10.32B | |
| Net Income TTM | $1.10B | $999M | · | $973M | $957M | $869M | · | $874M | $883M | $856M | · | $918M | $927M | $1.05B | · | $1.35B | |
| Market Cap | $23.31B | $21.75B | · | $21.15B | $20.12B | $18.95B | · | $17.39B | $15.19B | $14.78B | · | $13.65B | $15.74B | $15.85B | · | $13.99B | |
| Enterprise Value | $28.33B | $21.86B | · | $21.23B | $20.30B | $18.76B | · | $22.88B | $15.53B | $15.21B | · | $13.81B | $16.13B | $15.67B | · | $13.29B | |
| P/E | 21.8 | 22.2 | · | 22.3 | 21.3 | 22.0 | · | 20.2 | 17.6 | 17.7 | · | 15.3 | 17.7 | 16.0 | · | 11.1 | |
| P/S | 2.0 | 2.0 | · | 2.0 | 2.0 | 1.9 | · | 1.8 | 1.6 | 1.6 | · | 1.4 | 1.6 | 1.6 | · | 1.4 | |
| P/B | 3.1 | 3.0 | · | 2.9 | 2.8 | 2.7 | · | 2.6 | 2.3 | 2.3 | · | 2.1 | 2.5 | 2.6 | · | 2.2 | |
| P / Cash Flow | · | 78.3 | · | · | · | 60.4 | · | · | · | 95.9 | · | · | · | 168.6 | · | · | |
| P / FCF | · | 132.6 | · | · | · | 96.2 | · | · | · | 295.5 | · | · | · | -480.2 | · | · | |
| EV / EBITDA | 46.8 | 40.0 | · | 40.2 | 34.9 | 38.6 | · | 50.3 | 32.9 | 36.6 | · | 30.5 | 35.1 | 38.0 | · | 26.6 | |
| EV / FCF | · | 133.3 | · | · | · | 95.2 | · | · | · | 304.1 | · | · | · | -474.9 | · | · | |
| EV / Revenue | 2.5 | 2.0 | · | 2.0 | 2.0 | 1.9 | · | 2.4 | 1.7 | 1.6 | · | 1.5 | 1.7 | 1.6 | · | 1.3 | |
| Earnings Yield | 4.6% | 4.5% | · | 4.5% | 4.7% | 4.5% | · | 5.0% | 5.7% | 5.6% | · | 6.5% | 5.7% | 6.2% | · | 9.0% | |
| Payout Ratio | · | 34.9% | · | · | · | 38.2% | · | · | · | 40.7% | · | · | · | 36.6% | · | · |
Demonstrações Financeiras Demonstração de resultados, balanço patrimonial, fluxo de caixa — anual, últimos 5 anos
Demonstração de Resultados
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Receita | $11.04B | $9.87B | $9.25B | $9.88B | $10.79B |
| Margem Operacional % | 14.1% | 13.6% | 13.6% | 14.4% | 22.1% |
| Lucro líquido | $992M | $871M | $854M | $946M | $2.00B |
| EPS Diluído | $8.75 | $7.69 | $7.49 | $7.97 | $15.55 |
Balanço Patrimonial
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Dívida / Patrimônio Líquido | 0.8 | 0.9 | 0.7 | 0.7 | 0.6 |
| Índice de liquidez corrente | 1.0 | 1.1 | 1.3 | 1.2 | 1.6 |
| Índice de Liquidez Seca | 0.8 | 0.9 | 1.0 | 1.0 | 1.3 |
Fluxo de Caixa
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Fluxo de caixa livre | $1.36B | $909M | $864M | $1.31B | $1.83B |
Últimas notícias Notícias recentes mencionando esta empresa
Minhas Métricas Sua lista pessoal — linhas selecionadas de Fundamentos Completos
📊
Escolha as métricas que importam para você — clique no ➕ ao lado de qualquer linha em Fundamentos Completos acima.
Sua seleção é salva e acompanha você em todos os tickers.
Investidores institucionais (13F) 1.176 declarantes · $12.9B total · Em 30 de Junho de 2026
Instituições que relatam a posse desta ação em seu Formulário 13F trimestral da SEC. Apenas posições compradas; um único declarante pode aparecer duas vezes para opções separadas. Grandes posições de compra/venda compensatórias geralmente refletem market-making ou inventário protegido, não convicção direcional.
Atividade institucional — Q2 2026 vs trimestre anterior
| Novas posições | Posições encerradas | Aumentou | Diminuído | Variação líquida de ações |
|---|---|---|---|---|
| 115 (-25 vs trimestre anterior) | 64 (-17 vs trimestre anterior) | 415 (+69 vs trimestre anterior) | 333 (-20 vs trimestre anterior) | +7.5M |
Comparado a Q1 2026. Os registros do Formulário 13F da SEC devem ser feitos em até 45 dias após o final do trimestre, mais um pequeno período de tolerância para registrantes atrasados — trimestres ainda dentro desse período são ignorados em favor do par mais recente totalmente reportado.
| Instituição | Valor | Ações | % de 13F rastreado | Tipo |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $1.533.117.858 | 7.233.394 | 11,93% | Ações |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1.299.474.988 | 6.131.045 | 10,11% | Ações |
| STATE STREET CORP | $1.169.252.484 | 5.516.643 | 9,10% | Ações |
| GEODE CAPITAL MANAGEMENT, LLC | $584.135.885 | 2.767.754 | 4,54% | Ações |
| EdgePoint Investment Group Inc. | $476.372.038 | 2.247.568 | 3,71% | Ações |
| Grantham, Mayo, Van Otterloo & Co. LLC | $400.206.122 | 1.888.207 | 3,11% | Ações |
| DIMENSIONAL FUND ADVISORS LP | $357.050.202 | 1.684.597 | 2,78% | Ações |
| Davis Selected Advisers | $329.781.509 | 1.555.612 | 2,57% | Ações |
| VICTORY CAPITAL MANAGEMENT INC | $311.037.928 | 1.467.506 | 2,42% | Ações |
| NORGES BANK | $298.133.109 | 1.406.620 | 2,32% | Ações |
| FMR LLC | $227.315.614 | 1.072.496 | 1,77% | Ações |
| AMERICAN CENTURY COMPANIES INC | $173.422.135 | 818.220 | 1,35% | Ações |
| M&G PLC | $168.677.800 | 795.650 | 1,31% | Ações |
| VANGUARD FIDUCIARY TRUST CO | $131.756.386 | 621.639 | 1,03% | Ações |
| ALLIANCEBERNSTEIN L.P. | $122.662.706 | 625.894 | 0,95% | Ações |
| AMERIPRISE FINANCIAL INC | $109.652.758 | 517.352 | 0,85% | Ações |
| Woodline Partners LP | $102.974.000 | 485.841 | 0,80% | Ações |
| FIDUCIARY MANAGEMENT INC /WI/ | $102.489.906 | 483.557 | 0,80% | Ações |
| Artemis Investment Management LLP | $99.175.856 | 467.921 | 0,77% | Ações |
| CRAWFORD INVESTMENT COUNSEL INC | $97.514.204 | 460.081 | 0,76% | Ações |
| PRINCIPAL FINANCIAL GROUP INC | $91.995.201 | 434.042 | 0,72% | Ações |
| ENVESTNET ASSET MANAGEMENT INC | $90.834.224 | 428.564 | 0,71% | Ações |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $86.608.697 | 407.302 | 0,67% | Ações |
| BNP PARIBAS FINANCIAL MARKETS | $83.772.178 | 395.245 | 0,65% | Ações |
| M.D. Sass, LLC | $76.397.960 | 360.453 | 0,59% | Ações |
| Qube Research & Technologies Ltd | $72.783.206 | 343.398 | 0,57% | Ações |
| MACKENZIE FINANCIAL CORP | $70.641.875 | 333.295 | 0,55% | Ações |
| Advisors Capital Management, LLC | $69.429.626 | 327.575 | 0,54% | Ações |
| Swiss National Bank | $65.683.305 | 309.900 | 0,51% | Ações |
| Balyasny Asset Management L.P. | $58.364.883 | 275.371 | 0,45% | Ações |
| Mitsubishi UFJ Asset Management Co., Ltd. | $56.877.630 | 268.354 | 0,44% | Ações |
| RHUMBLINE ADVISERS | $56.744.612 | 267.727 | 0,44% | Ações |
| BlackRock, Inc. | $55.976.419 | 264.102 | 0,44% | Ações |
| Sumitomo Mitsui Trust Group, Inc. | $54.809.634 | 258.597 | 0,43% | Ações |
| VANGUARD ASSET MANAGEMENT, Ltd | $53.654.295 | 253.146 | 0,42% | Ações |
| Quantinno Capital Management LP | $53.607.358 | 252.924 | 0,42% | Ações |
| RAYMOND JAMES FINANCIAL INC | $53.249.860 | 251.238 | 0,41% | Ações |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $52.211.551 | 246.339 | 0,41% | Ações |
| VAN LANSCHOT KEMPEN INVESTMENT MANAGEMENT N.V. | $51.484.139 | 242.907 | 0,40% | Ações |
| Clark Capital Management Group, Inc. | $51.259.362 | 241.846 | 0,40% | Ações |
| Vanguard Global Advisers, LLC | $51.025.267 | 240.742 | 0,40% | Ações |
| Legal & General Group Plc | $50.185.731 | 236.781 | 0,39% | Ações |
| FIL Ltd | $49.419.958 | 233.168 | 0,38% | Ações |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $49.341.000 | 232.797 | 0,38% | Ações |
| Eurizon Capital SGR S.p.A. | $47.173.414 | 222.564 | 0,37% | Ações |
| BARCLAYS PLC | $45.003.978 | 212.333 | 0,35% | Ações |
| PFA Pension, Forsikringsaktieselskab | $43.579.660 | 205.613 | 0,34% | Ações |
| Integral Health Asset Management, LLC | $42.390.000 | 200.000 | 0,33% | Ações |
| California Public Employees Retirement System | $41.574.204 | 196.151 | 0,32% | Ações |
| CONNING INC. | $39.578.271 | 186.734 | 0,31% | Ações |
| SEB Asset Management AB | $38.766.863 | 182.906 | 0,30% | Ações |
| BANK OF MONTREAL /CAN/ | $38.512.587 | 181.706 | 0,30% | Ações |
| GOLDMAN SACHS GROUP INC | $38.322.295 | 180.808 | 0,30% | Ações |
| Boston Partners | $35.509.632 | 167.514 | 0,28% | Ações |
| Focus Partners Wealth | $34.616.947 | 163.327 | 0,27% | Ações |
| STOREBRAND ASSET MANAGEMENT AS | $34.117.592 | 160.970 | 0,27% | Ações |
| COOKSON PEIRCE & CO INC | $32.977.089 | 155.589 | 0,26% | Ações |
| UBS Group AG | $32.934.699 | 155.389 | 0,26% | Ações |
| BRAUN STACEY ASSOCIATES INC | $32.724.232 | 154.396 | 0,25% | Ações |
| Willis Investment Counsel | $32.110.425 | 151.500 | 0,25% | Ações |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $31.795.403 | 162.238 | 0,25% | Ações |
| LPL Financial LLC | $30.325.576 | 143.079 | 0,24% | Ações |
| APG Asset Management N.V. | $27.869.580 | 150.334 | 0,22% | Ações |
| SILVERCREST ASSET MANAGEMENT GROUP LLC | $26.893.912 | 126.888 | 0,21% | Ações |
| &PARTNERS | $26.382.365 | 124.363 | 0,21% | Ações |
| JANE STREET GROUP, LLC | $25.942.680 | 122.400 | 0,20% | Opção de compra |
| BANK OF AMERICA CORP /DE/ | $25.492.499 | 120.276 | 0,20% | Ações |
| Candriam S.C.A. | $25.459.925 | 120.238 | 0,20% | Ações |
| Squarepoint Ops LLC | $24.974.280 | 117.831 | 0,19% | Ações |
| Gotham Asset Management, LLC | $24.911.119 | 117.533 | 0,19% | Ações |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $24.607.896 | 116.373 | 0,19% | Ações |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | $24.569.456 | 115.921 | 0,19% | Ações |
| Robeco Institutional Asset Management B.V. | $23.854.123 | 112.546 | 0,19% | Ações |
| AEGON ASSET MANAGEMENT UK Plc | $22.866.862 | 107.888 | 0,18% | Ações |
| TOCQUEVILLE ASSET MANAGEMENT L.P. | $22.670.926 | 106.964 | 0,18% | Ações |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $22.530.921 | 106.303 | 0,18% | Ações |
| MERCER GLOBAL ADVISORS INC /ADV | $22.106.507 | 104.301 | 0,17% | Ações |
| Moran Wealth Management, LLC | $22.053.609 | 104.051 | 0,17% | Ações |
| ABN AMRO Bank N.V. | $21.523.733 | 101.667 | 0,17% | Ações |
| VIRGINIA RETIREMENT SYSTEMS ET Al | $21.496.202 | 123.876 | 0,17% | Ações |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $21.322.170 | 100.600 | 0,17% | Opção de compra |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $21.146.252 | 99.770 | 0,16% | Ações |
| AVIVA PLC | $20.378.569 | 96.148 | 0,16% | Ações |
| SCHWARTZ INVESTMENT COUNSEL INC | $20.326.005 | 95.900 | 0,16% | Ações |
| Boston Common Asset Management, LLC | $20.282.767 | 95.696 | 0,16% | Ações |
| CAPTRUST FINANCIAL ADVISORS | $20.146.790 | 95.054 | 0,16% | Ações |
| Midwest Trust Co | $20.113.207 | 94.896 | 0,16% | Ações |
| LAZARD ASSET MANAGEMENT LLC | $20.035.210 | 94.528 | 0,16% | Ações |
| FJARDE AP-FONDEN /FOURTH SWEDISH NATIONAL PENSION FUND | $19.842.759 | 93.620 | 0,15% | Ações |
| BLAIR WILLIAM & CO/IL | $19.773.115 | 93.291 | 0,15% | Ações |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $19.613.005 | 92.536 | 0,15% | Ações |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $19.160.280 | 90.400 | 0,15% | Opção de venda |
| CITADEL ADVISORS LLC | $18.821.160 | 88.800 | 0,15% | Opção de compra |
| WELLINGTON MANAGEMENT GROUP LLP | $17.507.282 | 82.601 | 0,14% | Ações |
| Foundry Partners, LLC | $17.338.432 | 102.473 | 0,13% | Ações |
| MARSHALL WACE, LLP | $17.187.874 | 81.094 | 0,13% | Ações |
| Coho Partners, Ltd. | $16.981.317 | 89.103 | 0,13% | Ações |
| Copeland Capital Management, LLC | $16.902.800 | 79.749 | 0,13% | Ações |
| CIBC Asset Management Inc | $16.674.318 | 78.671 | 0,13% | Ações |
| Mitsubishi UFJ Trust & Banking Corp | $16.558.594 | 78.125 | 0,13% | Ações |
Executivos da empresa 53 insiders · 26 diretores · 26 conselheiros
| Investidor com informação privilegiada | Função | Última atividade | Ações detidas | Compras 12m | Vendas 12m | Líquido 12m |
|---|---|---|---|---|---|---|
| E. J. Davis | CEO and President | 1 de Junho de 2026 S | 132.423 | 0 | 5 | $-14.656.302 |
| Surya N Mohapatra | Chairman, President & CEO | 30 de Abril de 2012 F | 243.713 | 0 | 0 | $0 |
| Sam Samad | Executive Vice President & CFO | 22 de Julho de 2026 A | 33.478 | 0 | 0 | $0 |
| Mark Guinan | Executive Vice President & CFO | 7 de Março de 2022 F | 98.981 | 0 | 0 | $0 |
| Robert Hagemann | SVP & Chief Financial Officer | 5 de Março de 2013 F | 126.722 | 0 | 0 | $0 |
| Mark E Delaney | SVP & Chief Commercial Officer | 28 de Julho de 2026 S | 10.335 | 0 | 1 | $-376.288 |
| Karthik Kuppusamy | SVP, Clinical Solutions | 22 de Julho de 2026 L | 13.557 | 0 | 2 | $-2.167.772 |
| Patrick Plewman | SVP for Diagnostic Services | 22 de Julho de 2026 L | 15.293 | 0 | 5 | $-2.390.549 |
| Catherine T. Doherty | EVP, Regional Businesses | 5 de Março de 2026 S | 67.122 | 0 | 7 | $-6.671.228 |
| Michael E Prevoznik | SVP & General Counsel | 5 de Março de 2026 S | 37.557 | 0 | 7 | $-6.505.199 |
| Michael J Deppe | SVP, Corp. Controller & CAO | 4 de Março de 2026 F | 35.196 | 0 | 0 | $0 |
| Mark A Gardner | SVP of Molecular Gen & Oncol | 24 de Setembro de 2024 F | 4.673 | 0 | 0 | $0 |
| Manner Carrie Eglinton | SVP, Advanced Diagnostics | 7 de Março de 2022 F | 48.391 | 0 | 0 | $0 |
| Manuel O. Mendez | SVP & Chief Commercial Officer | 17 de Fevereiro de 2021 A | 29.045 | 0 | 0 | $0 |
| Robert A Klug | VP, Corporate Controller | 1 de Março de 2019 F | 6.261 | 0 | 0 | $0 |
| Jon R Cohen | SVP & Group Exec. Diag. Sol. | 8 de Março de 2018 M | 31.757 | 0 | 0 | $0 |
| Everett Cunningham | SVP, Commercial | 1 de Março de 2018 G | 37.760 | 0 | 0 | $0 |
| Thomas F Bongiorno | VP and Corporate Controller | 2 de Março de 2015 F | 11.837 | 0 | 0 | $0 |
| John B. Haydon | SVP, Operations | 13 de Fevereiro de 2014 A | 19.890 | 0 | 0 | $0 |
| Kathy Ordonez | SVP, Diagnostic Solutions | 31 de Março de 2013 F | 9.569 | 0 | 0 | $0 |
| Joan Elizabeth Miller | SVP-Oncology & Neurology Srvcs | 29 de Fevereiro de 2012 F | 89.232 | 0 | 0 | $0 |
| Wayne R. Simmons | Vice President, Operations | 16 de Junho de 2011 M | 47.150 | 0 | 0 | $0 |
| Robert E Peters | VP, Sales & Marketing | 12 de Fevereiro de 2007 A | 12.974 | 0 | 0 | $0 |
| David M Zewe | SVP, Diagnostic Testing Ops | 12 de Fevereiro de 2007 A | 31.079 | 0 | 0 | $0 |
| GRANT THOMAS W II | Sr VP, Ins. & Employer Serv. | 12 de Fevereiro de 2007 A | — | 0 | 0 | $0 |
| Gerald C Marrone | SVP, Administration | 28 de Fevereiro de 2004 F | 49.609 | 0 | 0 | $0 |
| Wright Lassiter III | Conselheiro | 22 de Julho de 2026 L | 10.323 | 0 | 0 | $0 |
| Vicky B Gregg | Conselheiro | 22 de Julho de 2026 A | 18.386 | 0 | 1 | $-239.700 |
| Robert B Carter | Conselheiro | 22 de Julho de 2026 L | 3.864 | 0 | 0 | $0 |
| Timothy L Main | Conselheiro | 22 de Julho de 2026 L | 22.460 | 0 | 0 | $0 |
| Timothy C Wentworth | Conselheiro | 1 de Julho de 2026 A | 1.358 | 0 | 0 | $0 |
| Timothy M Ring | Conselheiro | 20 de Maio de 2026 A | 31.140 | 0 | 0 | $0 |
| Gary M Pfeiffer | Conselheiro | 20 de Maio de 2026 A | 31.005 | 0 | 1 | $-270.317 |
| Luis Diaz | Conselheiro | 15 de Maio de 2025 A | 4.054 | 0 | 0 | $0 |
| Tracey Doi | Conselheiro | 15 de Maio de 2025 A | 6.490 | 0 | 0 | $0 |
| Gail R Wilensky | Conselheiro | 17 de Maio de 2023 A | 20.506 | 0 | 0 | $0 |
| Stephen H Rusckowski | Conselheiro | 6 de Março de 2023 F | 389.597 | 0 | 0 | $0 |
| Helen Torley | Conselheiro | 25 de Maio de 2021 A | 6.260 | 0 | 0 | $0 |
| Daniel Stanzione | Conselheiro | 23 de Novembro de 2020 S | 28.349 | 0 | 0 | $0 |
| Jenne K Britell | Conselheiro | 4 de Junho de 2018 G | 14.479 | 0 | 0 | $0 |
| Jeffrey M Leiden | Conselheiro | 29 de Maio de 2018 S | 6.000 | 0 | 0 | $0 |
| John B Ziegler | Conselheiro | 22 de Fevereiro de 2017 S | 16.557 | 0 | 0 | $0 |
| John C Baldwin MD | Conselheiro | 12 de Agosto de 2015 S | 12.949 | 0 | 0 | $0 |
| William F Buehler | Conselheiro | 12 de Fevereiro de 2014 M | 26.225 | 0 | 0 | $0 |
| GSK plc | Conselheiro | 31 de Janeiro de 2011 S | 0 | 0 | 0 | $0 |
| Rosanne Haggerty | Conselheiro | 6 de Maio de 2010 A | 9.334 | 0 | 0 | $0 |
| William R Grant | Conselheiro | 1 de Abril de 2007 A | 3.334 | 0 | 0 | $0 |
| James F Flaherty III | Conselheiro | 4 de Maio de 2006 A | 1.667 | 0 | 0 | $0 |
| Kenneth D Brody | Conselheiro | 28 de Abril de 2004 S | 0 | 0 | 0 | $0 |
| Mary A Cirillo | Conselheiro | 1 de Abril de 2004 A | 2.627 | 0 | 0 | $0 |
Executivos de declarações SEC Formulário 3/4/5; líquido = apenas P/V de mercado aberto
Ativistas e proprietários de 5%+ 13 participações
Investidores que apresentaram o Schedule 13D da SEC — propriedade benéfica acima de 5% com a intenção de influenciar o emissor (participações ativistas, campanhas no conselho, M&A). Cada linha mostra o estado mais recente conhecido da posição desse declarante.
| Declarante | Declarado | Participação | Status | Propósito | Declaração |
|---|---|---|---|---|---|
| Quest Diagnostics Incorporated | 18 de Maio de 2011 | — | Declaração inicial | M&A / venda | SEC |
| Pessoa de relato não divulgada | 1 de Fevereiro de 2011 | — | Declaração inicial | Investimento passivo | SEC |
| Pessoa de relato não divulgada | 20 de Março de 2009 | — | Declaração inicial | — | SEC |
| GlaxoSmithKline plc ×2 declarações | 18 de Setembro de 2008 | — | Declaração inicial | — | SEC |
| Pessoa de relato não divulgada | 16 de Fevereiro de 2007 | — | Declaração inicial | — | SEC |
| Quest Diagnostics Incorporated - (FEIN No. ×2 declarações | 19 de Janeiro de 2006 | — | Declaração inicial | — | SEC |
| Pessoa de relato não divulgada | 15 de Dezembro de 2004 | — | Declaração inicial | — | SEC |
| Pessoa de relato não divulgada | 29 de Junho de 2004 | — | Declaração inicial | — | SEC |
| Pessoa de relato não divulgada | 24 de Junho de 2002 | — | Declaração inicial | M&A / venda | SEC |
| Pessoa de relato não divulgada | 22 de Maio de 2002 | — | Declaração inicial | — | SEC |
| Pessoa de relato não divulgada | 12 de Abril de 2002 | — | Declaração inicial | M&A / venda | SEC |
| IRS Identification Nos. of Above Persons (entities only) Quest Diagnostics Ventures LLC - (FEIN No., Quest Diagnostics Incorporated - (FEIN No. ×3 declarações | 1 de Novembro de 2001 | — | Declaração inicial | M&A / venda | SEC |
| Pessoa de relato não divulgada | 14 de Maio de 2001 | — | Declaração inicial | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Participação em ETFs Detido por 194 ETFs
O peso reflete apenas participações diretas em ações (N-PORT); fundos alavancados ou baseados em derivativos podem deter exposição adicional a swaps não mostrada.
| Fundo | Peso | Unidades | Em | Fonte |
|---|---|---|---|---|
| IHF · iShares Trust | 3,93% | 199.039 SH | 21 de Agosto de 2026 | Diário |
| FTDS · First Trust Exchange-Traded Fund | 2,17% | 3.760 NS | 30 de Junho de 2026 | N-PORT |
| RSPH · Invesco Exchange-Traded Fund Trust | 1,71% | 58.159 SH | 21 de Agosto de 2026 | Diário |
| GK · AdvisorShares Trust | 1,43% | 2.156 NS | 30 de Junho de 2026 | N-PORT |
| FXH · First Trust Exchange-Traded AlphaDE… | 1,29% | 57.932 NS | 30 de Abril de 2026 | N-PORT |
| CZA · Invesco Exchange-Traded Fund Trust | 1,24% | 9.488 SH | 21 de Agosto de 2026 | Diário |
| TMFX · RBB Fund, Inc. | 1,05% | 1.724 NS | 31 de Maio de 2026 | N-PORT |
| ANEW · ProShares Trust | 0,92% | 364 NS | 31 de Maio de 2026 | N-PORT |
| QLTY · GMO ETF Trust | 0,85% | 196.208 NS | 31 de Maio de 2026 | N-PORT |
| ALTL · Pacer Funds Trust | 0,82% | 4.047 NS | 30 de Abril de 2026 | N-PORT |
| LSEQ · Harbor ETF Trust | 0,80% | 635 NS | 30 de Abril de 2026 | N-PORT |
| SPVM · Invesco Exchange-Traded Fund Trust | 0,78% | 4.426 SH | 21 de Agosto de 2026 | Diário |
| QLV · FlexShares Trust | 0,74% | 6.461 NS | 30 de Abril de 2026 | N-PORT |
| GDOC · Goldman Sachs ETF Trust | 0,72% | 741 NS | 31 de Maio de 2026 | N-PORT |
| ESMV · iShares Trust | 0,72% | 236 SH | 21 de Agosto de 2026 | Diário |
| PAPI · Morgan Stanley ETF Trust | 0,56% | 10.542 NS | 30 de Junho de 2026 | N-PORT |
| HUSV · First Trust Exchange-Traded Fund III | 0,52% | 1.956 NS | 30 de Abril de 2026 | N-PORT |
| PRAY · FIS Trust | 0,47% | 1.958 NS | 31 de Maio de 2026 | N-PORT |
| ITAN · EA Series Trust | 0,46% | 2.110 NS | 29 de Maio de 2026 | N-PORT |
| BTAL · AGF Investments Trust | 0,46% | 6.072 NS | 30 de Junho de 2026 | N-PORT |
| KNGZ · First Trust Exchange-Traded Fund VI | 0,44% | 1.301 NS | 30 de Junho de 2026 | N-PORT |
| QQWZ · Pacer Funds Trust | 0,44% | 1.055 NS | 30 de Abril de 2026 | N-PORT |
| COWZ · Pacer Funds Trust | 0,44% | 409.814 NS | 30 de Abril de 2026 | N-PORT |
| FVD · First Trust Exchange-Traded Fund | 0,43% | 161.912 NS | 30 de Junho de 2026 | N-PORT |
| SIXL · EXCHANGE TRADED CONCEPTS TRUST | 0,41% | 3.999 NS | 31 de Maio de 2026 | N-PORT |
| IYH · iShares Trust | 0,41% | 65.931 SH | 21 de Agosto de 2026 | Diário |
| VOE · VANGUARD INDEX FUNDS | 0,40% | 711.079 SH | 19 de Agosto de 2026 | Diário |
| JPUS · J.P. Morgan Exchange-Traded Fund Tr… | 0,38% | 8.682 NS | 30 de Abril de 2026 | N-PORT |
| JPME · J.P. Morgan Exchange-Traded Fund Tr… | 0,37% | 8.368 NS | 30 de Abril de 2026 | N-PORT |
| IMCV · iShares Trust | 0,37% | 18.030 SH | 21 de Agosto de 2026 | Diário |
| SUSA · iShares Trust | 0,35% | 59.963 SH | 21 de Agosto de 2026 | Diário |
| FHLC · FIDELITY COVINGTON TRUST | 0,35% | 51.278 NS | 30 de Abril de 2026 | N-PORT |
| FTA · First Trust Exchange-Traded AlphaDE… | 0,34% | 23.030 NS | 30 de Abril de 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,34% | 330.273 SH | 19 de Agosto de 2026 | Diário |
| IXJ · iShares Trust | 0,32% | 58.047 SH | 21 de Agosto de 2026 | Diário |
| RXL · ProShares Trust | 0,31% | 1.147 NS | 31 de Maio de 2026 | N-PORT |
| CURE · Direxion Shares ETF Trust | 0,31% | 2.194 NS | 30 de Abril de 2026 | N-PORT |
| GNOM · Global X Funds | 0,28% | 789 NS | 31 de Maio de 2026 | N-PORT |
| DFLV · Dimensional ETF Trust | 0,26% | 79.983 NS | 30 de Abril de 2026 | N-PORT |
| BSCT · Invesco Exchange-Traded Self-Indexe… | 0,26% | 7.703.000 | 19 de Agosto de 2026 | Diário |
| IWS · iShares Trust | 0,25% | 166.379 SH | 21 de Agosto de 2026 | Diário |
| FEX · First Trust Exchange-Traded AlphaDE… | 0,24% | 18.806 NS | 30 de Abril de 2026 | N-PORT |
| JVAL · J.P. Morgan Exchange-Traded Fund Tr… | 0,24% | 8.995 NS | 30 de Abril de 2026 | N-PORT |
| EQIN · Columbia ETF Trust I | 0,23% | 3.340 NS | 30 de Abril de 2026 | N-PORT |
| CVMC · Morgan Stanley ETF Trust | 0,23% | 1.137 NS | 30 de Junho de 2026 | N-PORT |
| JMOM · J.P. Morgan Exchange-Traded Fund Tr… | 0,23% | 26.229 NS | 30 de Abril de 2026 | N-PORT |
| SIZE · iShares Trust | 0,23% | 4.242 SH | 21 de Agosto de 2026 | Diário |
| DFVE · DoubleLine ETF Trust | 0,23% | 351 NS | 30 de Junho de 2026 | N-PORT |
| VO · VANGUARD INDEX FUNDS | 0,23% | 2.398.948 SH | 19 de Agosto de 2026 | Diário |
| EUSA · iShares, Inc. | 0,22% | 18.045 SH | 21 de Agosto de 2026 | Diário |